ArticleBlood transfusion = Trasfusione del sangue2013
Sustainability of a public system for plasma collection, contract fractionation and plasma-derived medicinal product manufacturing.
Article in Blood transfusion = Trasfusione del sangue, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 13 citations in OpenAlex.
- Red Blood Cell-Induced Bacterial Margination Improves Microbial Hemoadsorption on Engineered Cell-Depleted Thrombi, Restoring Severe Bacteremia in Rats.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Securing commitment and control for the supply of plasma derivatives for public health systems. II: A survey of national pathways.Vox sanguinis · 2025Article
- Toward a Sociology of Plasma Products.International journal of social determinants of health and health services · 2024Article
- Shortage of plasma-derived medicinal products: what is next? narrative literature review on its causes and counteracting policies in Italy.Frontiers in pharmacology · 2024Review
- Using a scenario approach to assess for the current and future demand of immunoglobulins: An interview and literature study from The Netherlands.Transfusion medicine (Oxford, England) · 2022Review
- The growing importance of achieving national self-sufficiency in immunoglobulin in Italy. The emergence of a national imperative.Blood transfusion = Trasfusione del sangue · 2019Review
- Trends in Plasma Toll Fractionation for Self Sufficiency of Plasma-Derived Medicinal Products in Italy.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2019Article
- Plasma for fractionation in a public setting: cost analysis from the perspective of the third-party payer.Blood transfusion = Trasfusione del sangue · 2015Article
- Public expenditure for plasma-derived and recombinant medicinal products in Italy.Blood transfusion = Trasfusione del sangue · 2013Review
- Plasma and plasma-derived medicinal product self-sufficiency: the Italian case.Blood transfusion = Trasfusione del sangue · 2013Review
- Plasma-derived medicinal products self-sufficiency from national plasma: to what extent?Blood transfusion = Trasfusione del sangue · 2013Review
- Plasma-derived medicinal products: demand and clinical use.Blood transfusion = Trasfusione del sangue · 2013Article
- The demand for factor VIII and for factor IX and the toll fractionation product surplus management.Blood transfusion = Trasfusione del sangue · 2013Review
- Assessing operational readiness for plasma fractionation within Indonesia's National Transfusion Medicine System: a cross-sectional mixed-methods study.Blood transfusion = Trasfusione del sangueArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn Italy, the financial reimbursement for labile blood components exchanged between Regions is regulated by national tariffs defined in 1991 and updated in 1993-2003. Over the last five years, the need for establishing standard costs of healthcare services has arisen critically. In this perspective, the present study is aimed at defining both the costs of production of blood components and the related prices, as well as the prices of plasma-derived medicinal products obtained by national plasma, to be used for interregional financial reimbursement. MATERIALS AND
methodsIn order to analyse the costs of production of blood components, 12 out 318 blood establishments were selected in 8 Italian Regions. For each step of the production process, driving costs were identified and production costs were. To define the costs of plasma-derived medicinal products obtained by national plasma, industrial costs currently sustained by National Health Service for contract fractionation were taken into account.
resultsThe production costs of plasma-derived medicinal products obtained from national plasma showed a huge variability among blood establishments, which was much lower after standardization. The new suggested plasma tariffs were quite similar to those currently in force. Comparing the overall costs theoretically sustained by the National Health Service for plasma-derived medicinal products obtained from national plasma to current commercial costs, demonstrates that the national blood system could gain a 10% cost saving if it were able to produce plasma for fractionation within the standard costs defined in this study. DISCUSSION: Achieving national self-sufficiency through the production of plasma-derived medicinal products from national plasma, is a strategic goal of the National Health Service which must comply not only with quality, safety and availability requirements but also with the increasingly pressing need for economic sustainability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.